Sanara MedTech - SMTI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 48.35%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$29.66
▲ +0.78 (2.70%)

This chart shows the closing price for SMTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sanara MedTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SMTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SMTI

Analyst Price Target is $44.00
▲ +48.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sanara MedTech in the last 3 months. The average price target is $44.00, with a high forecast of $44.00 and a low forecast of $44.00. The average price target represents a 48.35% upside from the last price of $29.66.

This chart shows the closing price for SMTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Sanara MedTech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$44.00Low
3/27/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$49.00 ➝ $44.00Low
2/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$49.00Low
11/15/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$59.00 ➝ $49.00Low
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$59.00Low
8/17/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$59.00Low
7/15/2022Cantor FitzgeraldBoost Target$40.00 ➝ $50.00Low
5/2/2022Cantor FitzgeraldReiterated RatingOverweightLow
6/30/2021Cantor FitzgeraldInitiated CoverageOverweight$45.00Medium
(Data available from 7/15/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/16/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sanara MedTech logo
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Read More

Today's Range

Now: $29.66
Low: $28.35
High: $29.98

50 Day Range

MA: $29.79
Low: $26.86
High: $34.06

52 Week Range

Now: $29.66
Low: $26.06
High: $46.40

Volume

19,929 shs

Average Volume

16,096 shs

Market Capitalization

$255.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Sanara MedTech?

The following Wall Street analysts have issued reports on Sanara MedTech in the last year: Cantor Fitzgerald, and TheStreet.
View the latest analyst ratings for SMTI.

What is the current price target for Sanara MedTech?

1 Wall Street analysts have set twelve-month price targets for Sanara MedTech in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 48.3%. Cantor Fitzgerald has the highest price target set, predicting SMTI will reach $44.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $44.00 for Sanara MedTech in the next year.
View the latest price targets for SMTI.

What is the current consensus analyst rating for Sanara MedTech?

Sanara MedTech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SMTI will outperform the market and that investors should add to their positions of Sanara MedTech.
View the latest ratings for SMTI.

What other companies compete with Sanara MedTech?

How do I contact Sanara MedTech's investor relations team?

Sanara MedTech's physical mailing address is 1200 Summit Avenue Suite 414, Fort Worth TX, 76102. The company's listed phone number is (817) 529-2300 and its investor relations email address is [email protected]. The official website for Sanara MedTech is www.wndm.com. Learn More about contacing Sanara MedTech investor relations.